BioSpace News Archive

Kite, a Gilead Company, announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta®, the largest and longest follow-up of a CAR T-cell therapy versus standard of care in patients with relapsed or refractory large B-cell lymphoma.

CTI BioPharma Corp. announced an oral presentation and two poster presentations from the Company’s pacritinib program at the 64th American Society of Hematology Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022.

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases.

Blueprint Medicines Corporation announced AYVAKIT® data showing high, durable response rates and prolonged overall survival in patients with advanced systemic mastocytosis, including SM with an associated hematological neoplasm.

Ajax Therapeutics, Inc. announced the presentation of preclinical data on the company’s next generation Type II JAK2 inhibitor, AJ1-10502, at a poster session held today at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans.

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD117 and CD123 Shielded Cell & Immunotherapy Pairs program during this weekend’s American Society of Hematology meeting in New Orleans.